Rosenbach A, Dignard D, Pierce JV, Whiteway M, Kumamoto CA
The doses used in trials were around 500ug/kg, which means a 100kg person was receiving 50mg of the peptide daily. $50 million in research and development down the drain for a promising product that was no longer a viable pharmaceutical product
KEY BENEFITS FROM RESEARCH Enhances cell migration to injury sites Improves wound healing and tissue repair Supports new blood vessel formation Reduces tissue inflammation May support cardiovascular health KPV: THE INFLAMMATION CONTROLLER WHAT IT IS KPV is a tiny three-amino acid peptide (Lysine-Proline-Valine) that comes from a larger hormone that controls inflammation
Notably, these advantages persisted irrespective of baseline kidney function, HbA1c levels, BMI, the timing of DM diagnosis, comorbidities and concurrent medication, including immunosuppressants (Fig